

# Angelina Sontag

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9102066/angelina-sontag-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8 papers	101 citations	5 h-index	8 g-index
8 ext. papers	117 ext. citations	2.3 avg, IF	2.09 L-index

#	Paper	IF	Citations
8	Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol. <i>JMIR Research Protocols</i> , <b>2017</b> , 6, e195	2	4
7	Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. <i>Journal of Urology</i> , <b>2015</b> , 193, 1581-9	2.5	26
6	Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study. <i>BJU International</i> , <b>2014</b> , 114, 568-75	5.6	25
5	The role of initial success rates and other factors in determining reliability of outcomes of phosphodiesterase inhibitor therapy for erectile dysfunction: a pooled analysis of 17 placebo-controlled trials of tadalafil for use as needed. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 541-50	1.1	5
4	Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: validation of an anchor-based treatment responder classification. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 3029-37	1.1	7
3	Estimated risk of invasive breast cancer in postmenopausal women with and without family history of the disease. <i>Menopause</i> , <b>2011</b> , 18, 515-20	2.5	1
2	Benefits and risks of raloxifene by vertebral fracture status. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 71-6	2.5	7
1	First fractures among postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , <b>2010</b> , 28, 485-8	2.9	26